Targeting ATH3 for Neurodegenerative Diseases (G58158)

Target Name: NEUROD4

NCBI ID: G58158

NEUROD4

Targeting ATH3 for Neurodegenerative Diseases

Neurodegenerative diseases, such as Alzheimer's and Parkinson's, are some of the most significant health challenges that affect human society. These conditions are characterized by the progressive loss of brain cells, leading to a wide range of cognitive, behavioral, and motor symptoms. Despite advances in medical research, there is currently no cure for these diseases, and treatment options are limited to managing symptoms and improving quality of life.

One promising approach to treating neurodegenerative diseases is to target the neurotransmitters that are affected in these conditions. One such neurotransmitter is neurodegenerative neurotransmitter (NDN), which is a chemical messenger that transmits signals in the brain related to mood, emotion, and motivation.

One of the promising neurotransmitters that may be targeted for treatment is ATH3, which is a neurotransmitter that is affected in neurodegenerative diseases. ATH3 is a key mediator of emotional responses, and its levels have been linked to the development and progression of neurodegenerative diseases.

Research has shown that ATH3 levels are affected in a variety of neurodegenerative conditions, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Additionally, studies have shown that ATH3 levels are often decreased in individuals with neurodegenerative diseases, which suggests that these compounds may have a therapeutic potential.

Despite the promising results of ATH3 research, there is still much to be learned about this neurotransmitter. One of the main challenges in studying ATH3 is its role in neurodegenerative diseases is not well understood. Additionally, there is a lack of effective therapies that can target ATH3 directly, which makes it difficult to study its effects.

In conclusion, NEUROD4 (ATH3) is a neurotransmitter that is associated with a variety of neurodegenerative conditions. While more research is needed to fully understand its role in these conditions, targeting ATH3 with potential therapeutic compounds may be a promising approach to treating these diseases.

Protein Name: Neuronal Differentiation 4

Functions: Probably acts as a transcriptional activator. Mediates neuronal differentiation. Required for the regulation of amacrine cell fate specification in the retina (By similarity)

The "NEUROD4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NEUROD4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets